Adem Y Dawed1, Kaixin Zhou1, Nienke van Leeuwen2, Anubha Mahajan3, Neil Robertson3,4, Robert Koivula4,5, Petra J M Elders6, Simone P Rauh7, Angus G Jones8, Reinhard W Holl9, Julia C Stingl10, Paul W Franks5,11,12, Mark I McCarthy3,4,13, Leen M 't Hart2,7,14, Ewan R Pearson. 1. Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K. 2. Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands. 3. Wellcome Centre for Human Genetics, University of Oxford, Oxford, U.K. 4. Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, U.K. 5. Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Skåne University Hospital, Malmö, Lund University, Malmö, Sweden. 6. Department of General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Amsterdam University Medical Center, Amsterdam, the Netherlands. 7. Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam University Medical Center, Amsterdam, the Netherlands. 8. Institute of Clinical and Biological Sciences, University of Exeter Medical School, Exeter, U.K. 9. Institute of Epidemiology and Medical Biometry (ZIBMT), University of Ulm, Ulm, Germany, and German Center for Diabetes Research (DZD), München-Neuherberg, Germany. 10. Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany. 11. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. 12. Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA. 13. Oxford National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, U.K. 14. Section of Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
Abstract
OBJECTIVE: Gastrointestinal adverse effects occur in 20-30% of patients with metformin-treated type 2 diabetes, leading to premature discontinuation in 5-10% of the cases. Gastrointestinal intolerance may reflect localized high concentrations of metformin in the gut. We hypothesized that reduced transport of metformin via the plasma membrane monoamine transporter (PMAT) and organic cation transporter 1 (OCT1) could increase the risk of severe gastrointestinal adverse effects. RESEARCH DESIGN AND METHODS: The study included 286 severe metformin-intolerant and 1,128 metformin-tolerant individuals from the IMI DIRECT (Innovative Medicines Initiative: DIabetes REsearCh on patient straTification) consortium. We assessed the association of patient characteristics, concomitant medication, and the burden of mutations in the SLC29A4 and SLC22A1 genes on odds of intolerance. RESULTS: Women (P < 0.001) and older people (P < 0.001) were more likely to develop metformin intolerance. Concomitant use of transporter-inhibiting drugs increased the odds of intolerance (odds ratio [OR] 1.72, P < 0.001). In an adjusted logistic regression model, the G allele at rs3889348 (SLC29A4) was associated with gastrointestinal intolerance (OR 1.34, P = 0.005). rs3889348 is the top cis-expression quantitative trait locus for SLC29A4 in gut tissue where carriers of the G allele had reduced expression. Homozygous carriers of the G allele treated with transporter-inhibiting drugs had more than three times higher odds of intolerance compared with carriers of no G allele and not treated with inhibiting drugs (OR 3.23, P < 0.001). Use of a genetic risk score derived from rs3889348 and SLC22A1 variants found that the odds of intolerance were more than twice as high in individuals who carry three or more risk alleles compared with those carrying none (OR 2.15, P = 0.01). CONCLUSIONS: These results suggest that intestinal metformin transporters and concomitant medications play an important role in the gastrointestinal adverse effects of metformin.
OBJECTIVE:Gastrointestinal adverse effects occur in 20-30% of patients with metformin-treated type 2 diabetes, leading to premature discontinuation in 5-10% of the cases. Gastrointestinal intolerance may reflect localized high concentrations of metformin in the gut. We hypothesized that reduced transport of metformin via the plasma membrane monoamine transporter (PMAT) and organic cation transporter 1 (OCT1) could increase the risk of severe gastrointestinal adverse effects. RESEARCH DESIGN AND METHODS: The study included 286 severe metformin-intolerant and 1,128 metformin-tolerant individuals from the IMI DIRECT (Innovative Medicines Initiative: DIabetes REsearCh on patient straTification) consortium. We assessed the association of patient characteristics, concomitant medication, and the burden of mutations in the SLC29A4 and SLC22A1 genes on odds of intolerance. RESULTS:Women (P < 0.001) and older people (P < 0.001) were more likely to develop metformin intolerance. Concomitant use of transporter-inhibiting drugs increased the odds of intolerance (odds ratio [OR] 1.72, P < 0.001). In an adjusted logistic regression model, the G allele at rs3889348 (SLC29A4) was associated with gastrointestinal intolerance (OR 1.34, P = 0.005). rs3889348 is the top cis-expression quantitative trait locus for SLC29A4 in gut tissue where carriers of the G allele had reduced expression. Homozygous carriers of the G allele treated with transporter-inhibiting drugs had more than three times higher odds of intolerance compared with carriers of no G allele and not treated with inhibiting drugs (OR 3.23, P < 0.001). Use of a genetic risk score derived from rs3889348 and SLC22A1 variants found that the odds of intolerance were more than twice as high in individuals who carry three or more risk alleles compared with those carrying none (OR 2.15, P = 0.01). CONCLUSIONS: These results suggest that intestinal metformin transporters and concomitant medications play an important role in the gastrointestinal adverse effects of metformin.
Authors: James T Nguyen; Dan-Dan Tian; Rakshit S Tanna; Deena L Hadi; Sumit Bansal; Justina C Calamia; Christopher M Arian; Laura M Shireman; Bálint Molnár; Miklós Horváth; Joshua J Kellogg; Matthew E Layton; John R White; Nadja B Cech; Richard D Boyce; Jashvant D Unadkat; Kenneth E Thummel; Mary F Paine Journal: Clin Pharmacol Ther Date: 2020-12-23 Impact factor: 6.875
Authors: Jana Krüger; Markus Breunig; Lino Pascal Pasquini; Mareen Morawe; Alexander Groß; Frank Arnold; Ronan Russell; Thomas Seufferlein; Ninel Azoitei; Hans A Kestler; Cécile Julier; Sandra Heller; Meike Hohwieler; Alexander Kleger Journal: Cells Date: 2022-02-08 Impact factor: 6.600
Authors: Jasmin N Beaver; Brady L Weber; Matthew T Ford; Anna E Anello; Sarah K Kassis; T Lee Gilman Journal: Cells Date: 2022-06-09 Impact factor: 7.666
Authors: Sebastian Kalamajski; Mi Huang; Jonathan Dalla-Riva; Maria Keller; Adem Y Dawed; Ola Hansson; Ewan R Pearson; Hindrik Mulder; Paul W Franks Journal: Hum Mol Genet Date: 2022-02-21 Impact factor: 6.150